The Drug Discovery Problem
Traditional drug discovery takes 10 to 15 years and costs over $1 billion per approved drug, with a high failure rate. Most candidate compounds fail in late-stage clinical trials due to toxicity, efficacy, or pharmacokinetic problems that were not identified earlier. AI is being applied to accelerate and de-risk this pipeline at multiple stages.
Protein Structure Prediction
AlphaFold, developed by DeepMind, demonstrated that AI could predict the three-dimensional structure of proteins from their amino acid sequences with high accuracy. This was a landmark breakthrough. Protein structure is critical to understanding how drugs interact with biological targets. Access to predicted protein structures has accelerated target identification across pharmaceutical research.
De Novo Molecular Design
Generative AI models can propose novel molecular structures with desired properties. Rather than screening large libraries of existing compounds, these systems design molecules from scratch to match specified targets, binding affinity requirements, and ADMET profiles (absorption, distribution, metabolism, excretion, and toxicity).
Drug-Target Interaction Prediction
AI models can predict whether a candidate molecule will bind to a target protein and with what affinity. This can accelerate early screening and reduce the number of wet-lab experiments needed to identify viable candidates.
Clinical Trial Optimization
AI is being applied to patient recruitment for clinical trials by matching eligible patients to trial criteria in electronic health records. AI is also being used to optimize trial design, predict dropout risk, and identify biomarkers for patient stratification.
Current Limitations
AI drug discovery has produced several compounds that have entered clinical trials, but no AI-discovered drug has yet been approved as of early 2026. The clinical development phase remains the major bottleneck. AI can accelerate preclinical discovery but cannot yet predict clinical efficacy or safety with sufficient reliability to replace clinical testing.